# Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

> **NCT02223000** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 9 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBV 308 SE solution
- **DRUG:** BIBV 308 SE capsule 1
- **DRUG:** BIBV 308 SE capsule 2

## Key facts

- **NCT ID:** NCT02223000
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** 1998-07
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02223000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02223000, "Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02223000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*